Dynavax Technologies (DVAX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Dynavax Technologies faces a potential risk with its recently authorized share repurchase program, which aims to buy back up to $200 million of common stock. This initiative, while intended to bolster shareholder value, carries uncertainties regarding the actual number of shares repurchased and whether it will deliver the expected benefits. The program could inadvertently enhance stock price volatility and, if terminated, might lead to a decline in trading prices. Additionally, executing this program will deplete the company’s cash reserves, raising concerns about its overall financial strategy.
The average DVAX stock price target is $27.67, implying 112.68% upside potential.
To learn more about Dynavax Technologies’ risk factors, click here.
